UBS Group AG Has $8.14 Million Stock Position in Janux Therapeutics, Inc. $JANX

UBS Group AG grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 51.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 590,060 shares of the company’s stock after purchasing an additional 199,703 shares during the quarter. UBS Group AG owned about 0.98% of Janux Therapeutics worth $8,143,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Osaic Holdings Inc. boosted its stake in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares during the period. Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares during the period. Winthrop Capital Management LLC acquired a new stake in Janux Therapeutics during the 3rd quarter valued at $106,000. BNP Paribas Financial Markets lifted its holdings in Janux Therapeutics by 185.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after purchasing an additional 4,982 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after purchasing an additional 4,059 shares during the period. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $13.89 on Monday. The stock’s fifty day moving average price is $14.42 and its two-hundred day moving average price is $16.95. Janux Therapeutics, Inc. has a one year low of $12.12 and a one year high of $35.34. The firm has a market cap of $847.01 million, a price-to-earnings ratio of -7.55 and a beta of 2.58.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at $457,265.90. This represents a 5.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 7.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price objective for the company from $29.00 to $14.00 in a report on Monday, April 20th. Evercore set a $22.00 target price on shares of Janux Therapeutics in a report on Monday, May 11th. Cantor Fitzgerald decreased their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Guggenheim decreased their price target on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $45.85.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.